Oral News and Research

RSS

CTSI awards NYU one-year pilot grant to assess feasibility of hemoglobin A1C diabetes test

New York University's Clinical and Translational Science Institute has awarded an NYU nursing-dental research team a one-year pilot grant to assess the feasibility of using gingival crevicular blood from periodontal patients to gauge hemoglobin A1C -- a blood glucose measurement -- as a means of diagnosing diabetes and identifying pre-diabetes.

28 Feb 2011

FDA approves GSK's PROMACTA to treat rare blood disorder

GlaxoSmithKline today announced that the United States Food and Drug Administration granted full approval for PROMACTA, an oral tablet that can raise platelet counts in patients with the rare blood disorder chronic immune thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

27 Feb 2011

Experts offer myth-busting advice to fight against spring allergies

Millions of Americans sneeze and wheeze March through June when they use misinformation to manage their spring allergies.

27 Feb 2011

Takeda receives FDA approval for EDARBI to treat hypertension in adults

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the U.S. Food and Drug Administration approved EDARBI for the treatment of hypertension, or high blood pressure, in adults.

27 Feb 2011

Warner Chilcott fourth quarter revenue increases 1% to $694.4 million

Warner Chilcott plc today announced its results for the quarter and year ended December 31, 2010. As discussed more fully below, our financial position and results of operations in the quarter ended December 31, 2010 as compared to the prior year quarter were significantly impacted by several important transactions in 2009 and 2010.

25 Feb 2011

Journal of Clinical Virology publishes positive outcome from CMX001 treatment against AdV infection

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of the first reported case in which adenovirus infection was successfully eradicated following treatment with its broad-spectrum antiviral drug, CMX001.

25 Feb 2011

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Amgen today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA to Zometa in preventing bone complications called skeletal-related events in 1,901 men with prostate cancer and bone metastases.

25 Feb 2011

Study: AEG-1 expression predicts erlotinib treatment response in patients with EGFR-mutant lung cancer

Spanish researchers have identified a gene whose expression level strongly predicts how well certain lung cancer patients will respond to treatment with the drug erlotinib.

25 Feb 2011

Unigene accelerates UGP281 anorexigenic peptide to treat obese patients

Unigene Laboratories, Inc. announced today that the Company is accelerating the development of its lead proprietary anorexigenic peptide, UGP281.

25 Feb 2011

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer.

24 Feb 2011

Steroid administration may impact immune system in children with asthma

Children experiencing an asthma attack who are treated with a short burst of oral steroids may have a transient depression of immune response according to a new study led by Universit- de Montr-al.

24 Feb 2011

Positive results from Vertex VX-770 Phase 3 STRIVE study in patients with CF

Vertex Pharmaceuticals Incorporated today announced positive results from the Phase 3 STRIVE study of VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis.

24 Feb 2011

Stamford Hospital to participate in US FDA Expanded Access Treatment IND program for Generex Oral-lyn

Generex Biotechnology Corporation announced today that Stamford Hospital has agreed to participate in the United States Food and Drug Administration Expanded Access Treatment Investigational New Drug Program for Generex Oral-lyn, the Company's proprietary buccal insulin spray product for the treatment of patients with diabetes.

24 Feb 2011

Takeda submits NDA to FDA for fixed-dose combination of azilsartan medoxomil plus CLD to treat hypertension

Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc. U.S., submitted a New Drug Application to the U.S. Food and Drug Administration for an investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone for the treatment of hypertension, or high blood pressure.

24 Feb 2011

Sanofi Pasteur to participate in first international bell-ringing event to eradicate polio

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, today will participate in the first international bell-ringing event by a company listed on NYSE Euronext. The events will acknowledge past successes and future challenges in the battle to eradicate polio at the stock exchanges in New York, Paris, Brussels, Amsterdam and Lisbon.

24 Feb 2011

Judge upholds health law's insurance coverage requirement

A federal judge in Washington, D.C., became the third federal judge to uphold the constitutionality of the health overhaul's individual mandate. The decision was issued Tuesday evening.

24 Feb 2011

InfraReDx to showcase LipiScan IVUS Coronary Imaging System at CRT 2011

InfraReDx, Inc., a medical device company providing intelligent cardiovascular diagnostic imaging technologies, today announced that its LipiScan™ IVUS Coronary Imaging System will be featured in several presentations during the annual Cardiovascular Research Technologies (CRT) 2011 meeting, being held February 27 through March 1, 2011 at the Omni Shoreham Hotel in Washington, D.C.

24 Feb 2011

UCSF study shows increased contraceptive supply decreases unintended pregnancy rates

Rates of unintended pregnancies and abortions decrease significantly when women receive a one-year supply of oral contraceptives, instead of being prescribed one- or three-month supplies, a UCSF study shows.

24 Feb 2011

Polio: Myanmar plans vaccination campaign after confirming first new case in three years; India fights disease in rural areas

UNICEF said that Myanmar is planning a mass polio vaccination campaign of children under age five after the country confirmed its first case of the disease in three years, Agence France-Presse reports.

24 Feb 2011

Mass polio vaccination campaigns in Burma and Sudan

After a seven-month-old baby was diagnosed with polio, Myanmar is planning a mass polio vaccination said the United Nations Children’s Fund. UNICEF revealed that just one case is enough to trigger an “emergency response”, and health officials promptly vaccinated 10,000 children in the Mandalay region, central Myanmar, after the illness was first suspected in December 2010.

23 Feb 2011

Oral News and Research

CTSI awards NYU one-year pilot grant to assess feasibility of hemoglobin A1C diabetes test

FDA approves GSK's PROMACTA to treat rare blood disorder

Experts offer myth-busting advice to fight against spring allergies

Takeda receives FDA approval for EDARBI to treat hypertension in adults

Warner Chilcott fourth quarter revenue increases 1% to $694.4 million

Journal of Clinical Virology publishes positive outcome from CMX001 treatment against AdV infection

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Study: AEG-1 expression predicts erlotinib treatment response in patients with EGFR-mutant lung cancer

Unigene accelerates UGP281 anorexigenic peptide to treat obese patients

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

Steroid administration may impact immune system in children with asthma

Positive results from Vertex VX-770 Phase 3 STRIVE study in patients with CF

Stamford Hospital to participate in US FDA Expanded Access Treatment IND program for Generex Oral-lyn

Takeda submits NDA to FDA for fixed-dose combination of azilsartan medoxomil plus CLD to treat hypertension

Sanofi Pasteur to participate in first international bell-ringing event to eradicate polio

Judge upholds health law's insurance coverage requirement

InfraReDx to showcase LipiScan IVUS Coronary Imaging System at CRT 2011

UCSF study shows increased contraceptive supply decreases unintended pregnancy rates

Polio: Myanmar plans vaccination campaign after confirming first new case in three years; India fights disease in rural areas

Mass polio vaccination campaigns in Burma and Sudan

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News